Advanced drug delivery reviews最新文献_第10页

Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders 利用抗炎途径和巨噬细胞纳米输送治疗炎症和纤维化疾病。

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-09 DOI: 10.1016/j.addr.2024.115204

Ahmad Zaid, Amiram Ariel

{"title":"Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders","authors":"Ahmad Zaid, Amiram Ariel","doi":"10.1016/j.addr.2024.115204","DOIUrl":"10.1016/j.addr.2024.115204","url":null,"abstract":"<div><p>Targeting specific organs and cell types using nanotechnology and sophisticated delivery methods has been at the forefront of applicative biomedical sciences lately. Macrophages are an appealing target for immunomodulation by nanodelivery as they are heavily involved in various aspects of many diseases and are highly plastic in their nature. Their continuum of functional “polarization” states has been a research focus for many years yielding a profound understanding of various aspects of these cells. The ability of monocyte-derived macrophages to metamorphose from pro-inflammatory to reparative and consequently to pro-resolving effectors has raised significant interest in its therapeutic potential. Here, we briefly survey macrophages' ontogeny and various polarization phenotypes, highlighting their function in the inflammation-resolution shift. We review their inducing mediators, signaling pathways, and biological programs with emphasis on the nucleic acid sensing-IFN-I axis. We also portray the polarization spectrum of macrophages and the characteristics of their transition between different subtypes. Finally, we highlighted different current drug delivery methods for targeting macrophages with emphasis on nanotargeting that might lead to breakthroughs in the treatment of wound healing, bone regeneration, autoimmune, and fibrotic diseases.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":16.1,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139717256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revealing the clinical potential of high-resolution organoids 揭示高分辨率有机体的临床潜力

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-08 DOI: 10.1016/j.addr.2024.115202

Jihoon Ko , Sujin Hyung , Sunghun Cheong , Yoojin Chung , Noo Li Jeon

引用次数: 0

Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway 鼻内给药：纳米颗粒与鼻脑通路之间的相互作用。

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-07 DOI: 10.1016/j.addr.2024.115196

Yaoxing Chen , Chenyun Zhang , Yukun Huang , Yuxiao Ma , Qingxiang Song , Hongzhuan Chen , Gan Jiang , Xiaoling Gao

引用次数: 0

AcousticRobots: Smart acoustically powered micro-/nanoswimmers for precise biomedical applications 声学机器人：用于精确生物医学应用的智能声动力微型/纳米游泳器

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-06 DOI: 10.1016/j.addr.2024.115201

Gege Wu , Wei Xian , Qing You , Jingjing Zhang , Xiaoyuan Chen

{"title":"AcousticRobots: Smart acoustically powered micro-/nanoswimmers for precise biomedical applications","authors":"Gege Wu , Wei Xian , Qing You , Jingjing Zhang , Xiaoyuan Chen","doi":"10.1016/j.addr.2024.115201","DOIUrl":"10.1016/j.addr.2024.115201","url":null,"abstract":"<div><p>Although nanotechnology has evolutionarily progressed in biomedical field over the past decades, achieving satisfactory therapeutic effects remains difficult with limited delivery efficiency. Ultrasound could provide a deep penetration and maneuverable actuation to efficiently power micro-/nanoswimmers with little harm, offering an emerging and fascinating alternative to the active delivery platform. Recent advances in novel fabrication, controllable concepts like intelligent swarm and the integration of hybrid propulsions have promoted its function and potential for medical applications. In this review, we will summarize the mechanisms and types of ultrasonically propelled micro/nanorobots (termed here as “AcousticRobots”), including the interactions between AcousticRobots and acoustic field, practical design considerations (<em>e.g.</em>, component, size, shape), the synthetic methods, surface modification, controllable behaviors, and the advantages when combined with other propulsion approaches. The representative biomedical applications of functional AcousticRobots are also highlighted, including drug delivery, invasive surgery, eradication on the surrounding bio-environment, cell manipulation, detection, and imaging, <em>etc.</em> We conclude by discussing the challenges and outlook of AcousticRobots in biomedical applications.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":16.1,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139696304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From concept to early clinical trials: 30 years of microbubble-based ultrasound-mediated drug delivery research 从概念到早期临床试验：基于微泡的超声介导给药研究 30 年

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-05 DOI: 10.1016/j.addr.2024.115199

Ayache Bouakaz, Jean Michel Escoffre

{"title":"From concept to early clinical trials: 30 years of microbubble-based ultrasound-mediated drug delivery research","authors":"Ayache Bouakaz, Jean Michel Escoffre","doi":"10.1016/j.addr.2024.115199","DOIUrl":"10.1016/j.addr.2024.115199","url":null,"abstract":"<div><p>Ultrasound mediated drug delivery, a promising therapeutic modality, has evolved remarkably over the past three decades. Initially designed to enhance contrast in ultrasound imaging, microbubbles have emerged as a main vector for drug delivery, offering targeted therapy with minimized side effects. This review addresses the historical progression of this technology, emphasizing the pivotal role microbubbles play in augmenting drug extravasation and targeted delivery. We explore the complex mechanisms behind this technology, from stable and inertial cavitation to diverse acoustic phenomena, and their applications in medical fields. While the potential of ultrasound mediated drug delivery is undeniable, there are still challenges to overcome. Balancing therapeutic efficacy and safety and establishing standardized procedures are essential areas requiring attention. A multidisciplinary approach, gathering collaborations between researchers, engineers, and clinicians, is important for exploiting the full potential of this technology. In summary, this review highlights the potential of using ultrasound mediated drug delivery in improving patient care across various medical conditions.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":16.1,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24000218/pdfft?md5=564b495ee664f36c43b7f0ca16133c76&pid=1-s2.0-S0169409X24000218-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139690495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques 释放线粒体，实现基于纳米药物的治疗：克服生物学障碍、改进设计和选择验证技术

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-05 DOI: 10.1016/j.addr.2024.115195

Camilla Pegoraro, Inés Domingo-Ortí, Inmaculada Conejos-Sánchez, María J. Vicent

{"title":"Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques","authors":"Camilla Pegoraro, Inés Domingo-Ortí, Inmaculada Conejos-Sánchez, María J. Vicent","doi":"10.1016/j.addr.2024.115195","DOIUrl":"10.1016/j.addr.2024.115195","url":null,"abstract":"<div><p>Enhanced targeting approaches will support the treatment of diseases associated with dysfunctional mitochondria, which play critical roles in energy generation and cell survival. Obstacles to mitochondria-specific targeting include the presence of distinct biological barriers and the need to pass through (or avoid) various cell internalization mechanisms. A range of studies have reported the design of mitochondrially-targeted nanomedicines that navigate the complex routes required to influence mitochondrial function; nonetheless, a significant journey lies ahead before mitochondrially-targeted nanomedicines become suitable for clinical use. Moving swiftly forward will require safety studies, <em>in vivo</em> assays confirming effectiveness, and methodologies to validate mitochondria-targeted nanomedicines' subcellular location/activity. From a nanomedicine standpoint, we describe the biological routes involved (from administration to arrival within the mitochondria), the features influencing rational design, and the techniques used to identify/validate successful targeting. Overall, rationally-designed mitochondria-targeted-based nanomedicines hold great promise for precise subcellular therapeutic delivery.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":16.1,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24000176/pdfft?md5=96c1477b2a2644931d406c3ebd2a2c07&pid=1-s2.0-S0169409X24000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139690559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings 加速开发泊拉珠单抗维多汀的临床药理策略和主要研究结果摘要

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-03 DOI: 10.1016/j.addr.2024.115193

Michael Z. Liao , Dan Lu , Tong Lu , Leonid Gibiansky , Rong Deng , Divya Samineni , Randall Dere , Andy Lin , Jamie Hirata , Ben-Quan Shen , Donglu Zhang , Dongwei Li , Chunze Li , Dale Miles

{"title":"Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings","authors":"Michael Z. Liao , Dan Lu , Tong Lu , Leonid Gibiansky , Rong Deng , Divya Samineni , Randall Dere , Andy Lin , Jamie Hirata , Ben-Quan Shen , Donglu Zhang , Dongwei Li , Chunze Li , Dale Miles","doi":"10.1016/j.addr.2024.115193","DOIUrl":"10.1016/j.addr.2024.115193","url":null,"abstract":"<div><p>The favorable benefit–risk profile of polatuzumab vedotin, as demonstrated in a pivotal Phase Ib/II randomized study (GO29365; NCT02257567), coupled with the need for effective therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), prompted the need to accelerate polatuzumab vedotin development. An integrated, fit-for-purpose clinical pharmacology package was designed to support regulatory approval. To address key clinical pharmacology questions without dedicated clinical pharmacology studies, we leveraged non-clinical and clinical data for polatuzumab vedotin, published clinical data for brentuximab vedotin, a similar antibody–drug conjugate, and physiologically based pharmacokinetic and population pharmacokinetic modeling approaches. We review strategies and model-informed outcomes that contributed to regulatory approval of polatuzumab vedotin plus bendamustine and rituximab in R/R DLBCL. These strategies made polatuzumab vedotin available to patients earlier than previously possible; depending on the strength of available data and the regulatory/competitive environment, they may also prove useful in accelerating the development of other agents.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":16.1,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24000152/pdfft?md5=3292dcdbeb43a4f61c6918f8f9fc1790&pid=1-s2.0-S0169409X24000152-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139670636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond 用于癌症免疫疗法的 mRNA 运送系统：脂质纳米颗粒及其他

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-02-01 DOI: 10.1016/j.addr.2024.115190

Mariona Estapé Senti, Lucía García del Valle, Raymond M. Schiffelers

引用次数: 0

Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery 通过局部给药为治疗自身免疫性 1 型糖尿病的细胞移植提供免疫保护

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-01-28 DOI: 10.1016/j.addr.2024.115179

T.R. Lansberry , C.L. Stabler

{"title":"Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery","authors":"T.R. Lansberry , C.L. Stabler","doi":"10.1016/j.addr.2024.115179","DOIUrl":"10.1016/j.addr.2024.115179","url":null,"abstract":"<div><p><span>Type 1 diabetes mellitus<span> (T1DM) is an autoimmune condition that results in the destruction of insulin-secreting β cells of the islets of Langerhans. Allogeneic islet transplantation could be a successful treatment for T1DM; however, it is limited by the need for effective, permanent immunosuppression to prevent graft rejection. Upon transplantation, islets are rejected through non-specific, </span></span>alloantigen<span> specific, and recurring autoimmune pathways. Immunosuppressive agents used for islet transplantation are generally successful in inhibiting alloantigen rejection, but they are suboptimal in hindering non-specific and autoimmune pathways. In this review, we summarize the challenges with cellular immunological rejection and therapeutics used for islet transplantation. We highlight agents that target these three immune rejection pathways and how to package them for controlled, local delivery via biomaterials. Exploring macro-, micro-, and nano-scale immunomodulatory biomaterial platforms, we summarize their advantages, challenges, and future directions. We hypothesize that understanding their key features will help identify effective platforms to prevent islet graft rejection. Outcomes can further be translated to other cellular therapies beyond T1DM.</span></p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":16.1,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139568567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Steric stabilization of bioactive nanoparticles using elastin-like polypeptides 利用弹性蛋白样多肽对生物活性纳米粒子进行立体稳定化处理

IF 16.1 1区医学

Advanced drug delivery reviews Pub Date : 2024-01-26 DOI: 10.1016/j.addr.2024.115189

Alvin Phan , J. Andrew MacKay

引用次数: 0